Literature DB >> 10366409

Clinical and morphological features of undifferentiated monomorphous GH/TSH-secreting pituitary adenoma.

T Skorić1, M Korsić, K Zarković, V Plavsić, N Besenski, L Breskovac, Z Giljević, J Paladino.   

Abstract

A 41-year-old male presented with progressive visual defects, acromegaly and hyperthyroidism. After clinical evaluation a giant GH/TSH-secreting pituitary adenoma was diagnosed. Administration of the somatostatin analog octreotide at doses of 150 microg s.c. per day inhibited the secretion of both GH and TSH. A three-week treatment with octreotide prior to surgery led to slight visual improvement and CT scan showed some new necrotic areas within the tumor mass. Transcranial surgery was performed. By immunohistochemical analyses of the adenoma tissue GH, prolactin and beta-chorionic gonadotropin were detected; TSH was negative. Electron microscopy revealed an undifferentiated, monomorphous adenoma with morphological features of an acidophil stem cell adenoma such as the presence of misplaced exocytoses, fibrous bodies and mitochondrial gigantism. However, the tumor cells contained small secretory granules (up to 250 nm) accumulated along the cell membrane characteristic of thyrotrope cells. Furthermore, some adenoma cells were fusiform with long cytoplasmic processes resembling thyrotropes. Two months after the operation CT scan revealed a large residual tumor. Serum GH and TSH levels had increased again and the TSH level was even higher than before the treatment. The patient died suddenly, most probably of lethal arrhythmia. Specimens of the adenoma tissue obtained at autopsy confirmed the previous findings with the exception of positive immunostaining for TSH which was found in less than 1% of the adenoma cells. This undifferentiated, monomorphous GH/TSH-secreting pituitary adenoma represents an entity that is unusual both in its ultrastructural features and clinical manifestations suggesting a cytogenesis from an early, undifferentiated stem cell.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366409     DOI: 10.1530/eje.0.1400528

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  7 in total

1.  A rare case and a rapid tumor response to therapy: dramatic reduction in tumor size during octreotide treatment in a patient with TSH-secreting pituitary macroadenoma.

Authors:  Cihangir Erem; Arif Hacihasanoglu; Ahmet Sari; Halil Onder Ersöz; Kubilay Ukinç; Sami Fidan
Journal:  Endocrine       Date:  2004-11       Impact factor: 3.633

2.  Dissociated responsiveness of a growth hormone- and thyrotropin-secreting pituitary adenoma to octreotide-long-acting release therapy: the intriguing case of Mister B.

Authors:  L Curtò; M Ragonese; M Losa; F Trimarchi; S Cannavò
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

3.  Monomorphous Plurihormonal Pituitary Adenoma of Pit-1 Lineage in a Giant Adolescent with Central Hyperthyroidism.

Authors:  Bernardo Dias Pereira; Luísa Raimundo; Ozgur Mete; Ana Oliveira; Jorge Portugal; Sylvia L Asa
Journal:  Endocr Pathol       Date:  2016-03       Impact factor: 3.943

4.  Pituitary macroadenoma secreting thyrotropin and growth hormone: remission of bihormonal hypersecretion in response to lanreotide therapy.

Authors:  I Shimon; D Nass; D J Gross
Journal:  Pituitary       Date:  2001-09       Impact factor: 4.107

5.  Thyrotoxicosis with absence of clinical features of acromegaly in a TSH- and GH-secreting, invasive pituitary macroadenoma.

Authors:  Philip C Johnston; Amir H Hamrahian; Richard A Prayson; Laurence Kennedy; Robert J Weil
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2015-01-01

6.  Case Report: A Case of Pituitary Adenoma Producing Growth Hormone and Thyroid-Stimulating Hormone Simultaneously.

Authors:  Junpei Sanada; Fuminori Tatsumi; Shinji Kamei; Yoshiro Fushimi; Masashi Shimoda; Kenji Kohara; Shuhei Nakanishi; Kohei Kaku; Tomoatsu Mune; Hideaki Kaneto
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-22       Impact factor: 5.555

7.  Association study between common variations in some candidate genes and prostate adenocarcinoma predisposition through multi-stage approach in Iranian population.

Authors:  Behnaz Beikzadeh; Seyed Abdolhamid Angaji; Maryam Abolhasani
Journal:  BMC Med Genet       Date:  2020-04-15       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.